Ag Decision Maker, February 2009, Vol. 13, no. 4

A Business Newsletter for Agriculture

Ag Decision Maker, January 2009, Vol. 13, no. 3

A Business Newsletter for Agriculture

Ag Decision Maker, July 2009, Vol. 13, no. 9

A Business Newsletter for Agriculture

Ag Decision Maker, March 2009, Vol. 13, no. 5

A Business Newsletter for Agriculture

Ag Decision Maker, May 2009, Vol. 13, no. 7

A Business Newsletter for Agriculture

Ag Decision Maker, November 2008, Vol. 13, no. 1

A Business Newsletter for Agriculture

Ag Decision Maker, October 2009, Vol. 13, no. 12

A Business Newsletter for Agriculture

Ag Decision Maker, September 2009, Vol. 13, no. 11

A Business Newsletter for Agriculture

Desenvolvimento e exigências térmicas de Trichogramma pretiosum Riley, criados em duas traças do tomateiro

Estudou-se a biologia de Trichogramma pretiosum em ovos de Phthorimaea operculella (Zeller) e Tuta absoluta (Meyrick) em diferentes temperaturas (18, 20, 22, 25, 30 e 32ºC), 70±10% de umidade relativa e fotofase de 14 horas, com o objetivo de se determinarem as exigências térmicas, bem como o número de gerações durante o ano. Houve correlação inversa entre a duração do ciclo e o aumento de temperatura na faixa térmica estudada. A razão sexual, no entanto, não foi afetada pela temperatura quando o hospedeiro foi T. absoluta. A viabilidade de T. pretiosum, criado em P. operculella foi mais afetada que em T. absoluta. A exigência térmica, calculada pelo método da hipérbole, foi maior no tocante a T. absoluta (131,3 graus dia) em relação a P. operculella (120,9 graus dia), e o limiar térmico inferior, respectivamente, 12,98 e 13,53°C. No que tange a ambas as espécies de traças, a longevidade do parasitóide sempre obedeceu à distribuição de Weibull. O potencial de aumento foi avaliado, em ambas as espécies de traças, com base no número de gerações anuais.

FY13 Enrich Iowa Report State Funding for Iowa Libraries, January 13, 2014

This report illustrates the critical role of Enrich Iowa funding in enhancing lifelong learning for Iowans through libraries; improving library resources aimed at assisting job seekers; maintaining library hours that meet library customers’ needs; improving library technology services; and providing safe, accessible library buildings.

Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects

INTRODUCTION: The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose of the present paper is to discuss the results that have been obtained in normal volunteers with the specific angiotensin II receptor antagonist, losartan potassium. DOSE-FINDING: Over the last few years, studies in normotensive subjects have demonstrated that the minimal dose of losartan that produces maximal efficacy is 40-80 mg. Losartan has a long duration of action and its ability to produce a sustained blockade of the renin-angiotensin system is due almost exclusively to the active metabolite E3174. HORMONAL EFFECTS: Angiotensin II receptor blockade with losartan induces an expected increase in plasma renin activity and plasma angiotensin II levels. A decrease in plasma aldosterone levels has been found only with a high dose of losartan (120 mg). RENAL AND BLOOD PRESSURE EFFECTS: In normotensive subjects, losartan has little or no effect on blood pressure unless the subjects are markedly salt-depleted. Losartan causes no change in the glomerular filtration rate and either no modification or only a slight increase in renal blood flow. Losartan significantly increases urinary sodium excretion, however, and surprisingly produces a transient rise in urinary potassium excretion. Finally, losartan increases uric acid excretion and lowers plasma uric acid levels. CONCLUSIONS: These results suggest that losartan is an effective angiotensin II receptor antagonist in normal subjects. Its safety and clinical efficacy in hypertensive patients will be addressed in large clinical trials.

Aging Watch, December 20, 2013, Vol. 13, no. 14

Aging Watch is provided in the spirit of information and education. The opinions expressed by the contributors do not necessarily reflect those of the Department or its programs. The Department shall not be liable for any damages that may result from errors or omissions in information distributed in this publication. Aging Watch will be published regularly during the legislative session and monthly in the interim by the Iowa Department on Aging. “Aging Watch.” The Department is providing this update to better inform you about policy affecting older Iowans. In addition to policy updates from the statehouse and the nation’s capitol, you’ll learn about Department programs and changes affecting the landscape. As you’ll learn reading this and future editions, big changes are coming for the Iowa Aging Network. Over the next year the Department will be reducing the number of local Area Agencies on Aging, as required by legislative action. Not surprisingly, this is a major change for everyone.

Aging Watch, June 11, 2013, Vol. 13, no. 12

Aging Watch is provided in the spirit of information and education. The opinions expressed by the contributors do not necessarily reflect those of the Department or its programs. The Department shall not be liable for any damages that may result from errors or omissions in information distributed in this publication. Aging Watch will be published regularly during the legislative session and monthly in the interim by the Iowa Department on Aging. “Aging Watch.” The Department is providing this update to better inform you about policy affecting older Iowans. In addition to policy updates from the statehouse and the nation’s capitol, you’ll learn about Department programs and changes affecting the landscape. As you’ll learn reading this and future editions, big changes are coming for the Iowa Aging Network. Over the next year the Department will be reducing the number of local Area Agencies on Aging, as required by legislative action. Not surprisingly, this is a major change for everyone.